|
In Vitro Activity of the New Azole BAL4815 and other Antifungal Agents against Candida Bloodstream Isolates (click for details) |
|
|
|
In Vitro Activity of the New Azole Isavuconazole (BAL 4815) Compared with Six other Antifungal Agents against 155 Cryptococcus neoformans Isolates from Cuba (click for details) |
|
|
|
Variable Effects of Voriconazole (VRC) and Caspofungin (CAS) on Cytokine and Chemokine Release by Human Monocytes (MNCs) in Response to Aspergillus Fumigatus (AF).
(click for details) |
|
|
|
Histone Modifications Regulate Antifungal Sensitivity and MDR Gene Expression in Candida Glabrata.
(click for details) |
|
|
|
Paradoxical Growth (PG) of Candida Tropicalis (Ct) in Response to Micafungin (MCFG).
(click for details) |
|
|
|
Polimerase Chain Reaction (PCR) in the Diagnosis of Invasive Aspergillosis (IA): A Meta-Analysis.
(click for details) |
|
|
|
Epidemiology and Outcome of Zygomycosis (Z) in a Tertiary Care Cancer Center (1989-2006): A Retrospective Study of 95 Episodes. (click for details) |
|
|
|
In Vitro Activity of Anidulafungin and Caspofungin in Candida Species: There is a Significant Correlation Between the Activity of Both Candins?
(click for details) |
|
|
|
Pharmacokinetics (PK) and Safety of Posaconazole (POS) as Prophylaxis for Invasive Fungal Infection (IFI) in High-Risk Patients (Pts).
(click for details) |
|
|
|
Global Surveillance of the In Vitro Activity of Micafungin against Candida: A Comparison with Caspofungin Using Clinical and Laboratory Standards Institute Recommended Methods.
(click for details) |
|
|
